Introduction: To assess the impact on hospitalization costs of multimodal analgesia
INTRODUCTION
The Institute for Healthcare Improvement (IHI) Triple Aim requires simultaneous pursuit of (1) improving the patient care experience, (2) advancing population health, and (3) reducing per capita costs of healthcare [1, 2] . In the context of postoperative pain management, current practice guidelines and recommendations from professional groups and agencies across disciplines such as the American Academy of Orthopaedic Surgeons [3, 4] , American Society of Anesthesiologists [5] , American College of Critical Care Medicine [6] shortening length of stay (LOS) [15] . In addition to other widely used pain medications, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs) (used as early as the 1960s [16] ) and some neurologic agents (e.g., gabapentin and pregabalin), acetaminophen (APAP), a centrally-acting analgesic agent, is commonly employed in postoperative MMA [7, 17] . In certain patients, including those for whom use of NSAIDs may be inadvisable or contraindicated (e.g., patients with certain cardiac diseases or who have undergone coronary artery bypass graft surgery) [6, [18] [19] [20] [28] . Randomized clinical trials of IV-APAP have also yielded evidence of improved patient satisfaction [29] .
The orthopedic surgical procedures total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip repair rank among the 12 most commonly performed inpatient surgical procedures in the US, together accounting for more than 1.4 million hospital stays annually, according to the most recent data (2012) from the Healthcare Cost and Utilization Project [30] . 
Study Cohorts
Patients were categorized by the postoperative pain management regimen received: a combination of IV-APAP plus other analgesics (which could include both IV and oral analgesics) (IV-APAP group) or IV opioid monotherapy (IV opioid monotherapy group).
Patients who also received IV NSAIDs were excluded from the IV opioid group, as this group was intended to represent patients receiving monotherapy with IV opioids.
Patients in either cohort could have also received oral analgesics (e.g., hydromorphone, oxycodone, hydrocodone, NSAIDs) as part of the postoperative pain management regimen.
To be eligible, patients had to have started IV analgesia on postoperative day 0 (i.e., the same day as surgery).
Variables
The following data from the HDD were included in this analysis: patient demographics, geographic region, payer type, hospital size, setting type, teaching status, and year of surgical procedure. Cost data included total hospitalization costs, which comprised medical costs and pharmacy costs. Medical costs included medical/surgical supplies, laboratory, imaging, and other costs (including room and board, operating room, therapy/ respiratory therapy, and miscellaneous/routine costs). Costs were analyzed for the index admission only and were adjusted to 2014 US dollars using the medical component of the Consumer Price Index (United States
Department of Labor). Costs represent what it
costs the hospital to provide care to the patient, independent of insurance type or status.
Statistical Analysis
Descriptive statistics were used to characterize the study sample during the baseline period and to compare treatment groups in terms of demographic, payer, and hospital characteristics. Differences in categorical variables were assessed using the Chi square test, while differences in continuous variables (including unadjusted differences in hospitalization costs) were assessed using the Student's t test. The a priori statistical significance level was set at a = 0.05.
In the adjusted analysis of hospitalization costs, inverse probability treatment weighting (IPTW) with propensity scores was used to account for potential confounding while retaining the entire sample of patients. The propensity score was defined as the probability of being treated with IV-APAP, conditional on the individual's baseline characteristics (age at index admission, year of index admission, and index payer), and the score was derived from a logistic regression model. A weight was then calculated for each individual as the inverse of the individual's propensity score [32] . These weights were used to create a synthetic sample in which the distribution of measured baseline covariates was independent of treatment assignment. This adjusted analysis controlled for age, gender, region, payer, year of index admission, setting type, teaching status, and hospital size. Table 1 . Statistically significant differences between treatment groups were noted for all baseline characteristics. However, the large sample sizes confer greater likelihood of attaining statistically significant differences, irrespective of whether numerical differences observed are meaningful in clinical or practical terms [33] . Standardized differences for these baseline characteristics are also included in Table 1 . A standardized difference of 10% (or 0.1) is considered equivalent to a P value of 0.05, indicating insignificant correlation [34] . The only readily discerned noteworthy difference between the treatment groups was that patients in the IV-APAP group tended to have had admissions during the latter 2 years of the study period; in this group, 65.1% of index admissions occurred in 2013 or 2014, compared with 33.2% in the IV opioid monotherapy group.
RESULTS

Sample Selection
Unadjusted total, medical, and pharmacy costs for the IV-APAP and IV opioid monotherapy groups are shown in Table 2 . Total mean [±standard deviation (SD)] hospitalization cost was significantly lower (P\0.0001) for patients in the IV-APAP group compared with those in the IV opioid monotherapy group ($12,540 ± $9564 vs.
$13,242 ± $35,825), which represents an approximately $702 lower total cost for the IV-APAP group. The difference in total costs was almost completely accounted for by medical costs, which were $701 lower in the IV-APAP group than in the IV opioid monotherapy group (P\0.0001). Within the medical cost category, the largest between-group absolute difference was in ''other'' costs (room and board, operating room costs, therapy and respiratory therapy costs, and miscellaneous/routine costs), which were $571 lower for the IV-APAP group (P\0.0001). Of note, pharmacy costs were comparable between the treatment groups ($486 for the IV-APAP group and $488 for the IV opioid monotherapy group).
In the adjusted analysis using IPTW with propensity scores, total hospitalization costs ( hospitalization cost differences seen in the initial, unadjusted analysis.
As the acquisition cost of IV-APAP is higher, the economic implications of its utilization have been of interest to healthcare institutions and systems [35] . opioids (n = 174,805) with those who received IV opioid monotherapy (n = 311,090) [36] corroborate the current study findings of significantly lower hospitalization costs for the patients who received IV-APAP. Another hospital database analysis of patients who underwent elective major joint arthroplasty found that patients who received IV-APAP had total hospitalization costs that were significantly lower than similar patients who did not receive IV-APAP [37] . While the current analysis did not allow for the elucidation of the factors underlying reduced hospitalization cost in IV-APAP-treated patients, previous analyses have found reduced LOS for such patients [36] and significantly fewer adverse events [37] .
A possible cost factor more directly related to use of IV-APAP is opioid consumption [38] . Reduction in morphine requirement with use of IV-APAP formed the basis of a recent pharmacoeconomic modeling study [38] . The study derived data from de-identified records from more than 2 million inpatient surgical encounters at 297 hospitals, including more than 270,000 in which use of IV-APAP was documented. The results indicate that use of IV-APAP and reduction in morphine Table 5 for details on oral analgesics received). Therefore, it was not possible to ascertain differences in hospitalization costs directly due to IV-APAP.
It is of note that a larger proportion of the study patients who received IV opioid monotherapy were observed during the earlier 
Limitations
This analysis was limited to patients admitted to those hospitals providing data to the HDD, so generalizability of the results to all patients undergoing orthopedic surgery may be limited. The HDD represents nearly 11% of the approximately 5,600 registered hospitals in the US [31] ; hospitals in the Northeast are slightly overrepresented, compared with the universe of hospitals in the US, as are hospitals with fewer beds, although institutions in the HDD are generally the same with regard to patient age and gender [31, 39] . Additionally, this study assessed hospitalization costs only and could not account for healthcare utilization or costs post-discharge. Additional research is also needed to characterize mechanisms by which MMA including IV-APAP may influence hospitalization costs and other outcomes. 
